Prevention of opportunistic infections in HIV infection by pentoxiphylline

Indian Journal of Medical Research

Volumn 124, Issue DEC., 2006, Pages 705-708

  Wanchu, A ^a   Bhatnagar, A ^a   Bambery, P ^a   Singh, S ^a   Varma, S ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

Anti TNF therapy; HIV; Opportunistic infections; Pentoxiphylline

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; EFAVIRENZ; NEVIRAPINE; PENTOXIFYLLINE; PLACEBO; PROTEINASE INHIBITOR; TUBERCULOSTATIC AGENT; TUMOR NECROSIS FACTOR ALPHA;

ABDOMINAL DISCOMFORT; ADULT; APPETITE DISORDER; ARTICLE; BODY WEIGHT; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRYPTOCOCCAL MENINGITIS; DRUG COST; FATIGUE; FEMALE; FLOW CYTOMETRY; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INDIVIDUALITY; LUNG TUBERCULOSIS; MALAISE; MALE; OPPORTUNISTIC INFECTION; PRESCRIPTION; SEX DIFFERENCE; SYMPTOMATOLOGY; AIDS RELATED COMPLEX; DRUG ANTAGONISM; IMMUNOLOGY; MIDDLE AGED;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; CD4 LYMPHOCYTE COUNT; FEMALE; HUMANS; MALE; MIDDLE AGED; PENTOXIFYLLINE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 34247166603     PISSN: 09715916     EISSN: 09715916     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Joint UN Programme on HIV/AIDS. Available at www.unaids.org (accessed 15th September 2005).
2. Harries AD, Hargreaves NJ, Kemp J, Jindani A, Enavson DA, Maher D, et al. Deaths from tuberculosis in sub-Saharan African countries with a high prevalence of HIV-1. Lancet 2001; 357: 1519-23.
3. Szondy Z, Toth R, Szegezdi E, Reichert U, Ancian P, Fesus L. Cell death in HIV pathogenesis and its modulation by retinoids. Ann NY Acad Sci 2001; 946: 95-107.
4. de Olivera Pinto LM, Garcia S, Lecoeur H, Rapp C, Gougeon ML. Increased sensitivity of T lymphocytes to tumor necrosis factor receptor 1 (TNFR1)- and TNFR2-mediated apoptosis in HIV infection: relation to expression of Bcl-2 and active caspase-8 and caspase-3. Blood 2002; 99: 1666-75.
5. Scheller C, Sopper S, Chen P, Flory E, Koutsilieri E, Racek T, et al. Caspase inhibition activates HIV in latently infected cells. Role of tumor necrosis factor receptor 1 and CD 95. J Biol Chem 2002; 277: 15459-64.
6. Oyaizu N, Pahwa P. Role of apoptosis in HIV disease pathogenesis. J Clin Immunol 1995; 15: 217-31.
7. Lahdebirta J, Maury CPJ, Anna-Maija T, Repo H. Elevated levels of circulating cachechin/tumor necrosis factor in patients with acquired immunodeficiency syndromes. Am J Med 1998; 85: 289-91.
8. Balog DL, Epstein ME, Amodio-Groton MI. HIV wasting syndrome: treatment update. Ann Pharmacotherapy 1998; 32: 446-58.
9. Eigler A, Sinha B, Hartmann G, Endres A. Taming TNF: Strategies to restrain this proinflammatory cytokine. Immunol Today 1997; 18: 487-92.
10. Han J, Thompson P, Bewtler B. Dexamethasone and pentoxyphylline inhibit endotoxin-induced cachectin/tumor necrosis factor synthesis at separate points in the signalling pathway. J Exp Med 1998; 170: 391-4.
11. Heinkelein M, Schneider-Schaulies J, Walker BD, Jassoy C. Inhibition of cytotoxicity and cytokine release of CD8+HIV-specific cytotoxic T lymphocytes by pentoxiphylline. J Acquir Immune Defic Syndr Hum Retrovirol 1995; 10: 417-24.
12. Clerici M, Pilconi S, Balotta C, Trabattoni D, Capetti A, Fusi ML, et al. Pentoxiphylline improves cell-mediated immunity and reduces human immunodeficiency virus (HIV) plasma viremia in asymptomatic HIV-seropositive persons. J Infect Dis 1997; 175: 1210-5.
13. Navarro J, Punzon MC, Pizarroo A, Fermandes-Cruz E, Fresno M, Munoz-Fernandes MA, et al. Pentoxiphylline inhibits acute HIV-1 replication in human T cells by a mechanism not involving inhibition of tumour necrosis factor synthesis or nuclear factor-kappa B activation. AIDS 1996; 10: 469-75.
14. Lemp GF, Payne SF, Neal D, Temelso T, Rutherford GW. Survival trends for patients with AIDS. JAMA 1990; 263: 402-6.
15. Fauci AS. Immunopathogenetic mechanisms in human immunodeficiency virus (HIV) infection. Ann Int Med 1991; 114: 678-93.
16. Tindall B, Cooper DA. Primary HIV infection: host responses and intervention strategies. AIDS 1991; 5: 1-4.
17. Wanchu A, Khullar M, Bhatnagar A, Sud A, Bambery P, Singh S. Pentoxiphylline reduces nitric oxide production among patients with HIV infection. Immunology Lett 2000; 74: 121-5.
18. Wanchu A, Arora S, Bhatnagar A, Sud A, Bambery P, Singh S. Suppression of beta-2 microglobulin by pentoxiphylline therapy in asymptomatic HIV infected individuals. Indian J Med Res 2001; 113: 75-7.
19. Fahey JL, Taylor JMG, Detels R, Hofmann B, Melmed R, Nishinain P, et al. The prognostic value of cellular and serologic markers in infection with human immunodeficiency virus type I. N Engl J Med 1990; 322: 166-72.
20. Melmed RN, Taylor JM, Detels R, Bozorgmehri M, Fahey JL. Serum neopterin changes in HIV-infected subjects: indicator of significant pathology, CD4 T cell change, and development of AIDS. J Acqir Immune Defic Syndr 1989; 2: 70-6.
21. Wanchu A, Bhatnagar A, Kumar B, Bambery P, Singh S. Reduced apoptosis by pentoxiphylline among patients with HIV infection. Int Immunopharmacol 2003; 3: 349-54.